Involvement of ADAMs in tumorigenesis and progression of hepatocellular carcinoma: Is it merely fortuitous or a real pathogenic link?

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1806, Issue 1, 2010, Pages 74-81

  Mazzocca, Antonio ^a   Giannelli, Gianluigi ^a   Antonaci, Salvatore ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

ADAMs; Cancer associated myo fibroblasts; Hepatocellular carcinoma; Invasion; Metastasis; Tumor stromal interactions

Indexed keywords

ADAM PROTEIN; ADAM10 ENDOPEPTIDASE; ADAM12 PROTEIN; ADAM15 PROTEIN; ADAM17 PROTEIN; ADAM19 PROTEIN; ADAM28 PROTEIN; ADAM8 PROTEIN; ADAM9 PROTEIN; UNCLASSIFIED DRUG;

AUTOCRINE EFFECT; CANCER INVASION; CHRONIC INFLAMMATION; COLON CARCINOMA; DISTANT METASTASIS; EXTRACELLULAR MATRIX; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER METASTASIS; MALIGNANT TRANSFORMATION; MYOFIBROBLAST; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; TUMOR GROWTH;

ADAM PROTEINS; ANIMALS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; HUMANS; LIVER NEOPLASMS; STROMAL CELLS;

CERCOPITHECINE HERPESVIRUS 1; HEPATITIS C VIRUS;

EID: 77953719505     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2010.02.002     Document Type: Review

References (91)

1. Stöcker W., Grams F., Baumann U., Reinemer P., Gomis-Rüth F.X., McKay D.B., Bode W. The metzincins-topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. Protein Sci. 1995, 4:823-840.
2. Blobel C.P. ADAMs: key components in EGFR signalling and development. Nat. Rev. Mol. Cell. Biol. 2005, 6:32-43.
3. Seals D.F., Courtneidge S.A. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 2003, 17:7-30.
4. Edwards D.R., Handsley M.M., Pennington C.J. The ADAM metalloproteinases. Mol. Aspects Med. 2008, 29:258-289.
5. Duffy M.J., Lynn D.J., Lloyd A.T., O'Shea C.M. The ADAMs family of proteins: from basic studies to potential clinical applications. Thromb. Haemost. 2003, 89:622-631.
6. Tousseyn T., Jorissen E., Reiss K., Hartmann D. (Make) stick and cut loose-disintegrin metalloproteases in development and disease. Birth Defects Res. C Embryo Today 2006, 78:24-46.
7. Rocks N., Paulissen G., El Hour M., Quesada F., Crahay C., Gueders M., Foidart J.M., Noel A., Cataldo D. Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie 2008, 90:369-379.
8. Mochizuki S., Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci. 2007, 98:621-628.
9. Arribas J., Bech-Serra J.J., Santiago-Josefat B. ADAMs, cell migration and cancer. Cancer Metastasis Rev. 2006, 25:57-68.
10. Duffy M.J., McKiernan E., O'Donovan N., McGowan P.M. Role of ADAMs in cancer formation and progression. Clin. Cancer Res. 2009, 15:1140-1144.
11. Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat. Rev. Cancer 2008, 8:929-941.
12. Huovila A.P., Turner A.J., Pelto-Huikko M., Karkkainen I., Ortiz R.M. Shedding light on ADAM metalloproteinases. Trends Biochem. Sci. 2005, 30:413-422.
13. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., Castner B.J., Stocking K.L., Reddy P., Srinivasan S., Nelson N., Boiani N., Schooley K.A., Gerhart M., Davis R., Fitzner J.N., Johnson R., Paxton J., March C.J., Cerretti D.P. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cell. Nature 1997, 385:729-733.
14. Moss M.L., Jin S.L., Milla M.E., Bickett D.M., Burkhart W., Carter H.L., Chen W.J., Clay W.C., Didsbury J.R., Hassler D., Hoffman C.R., Kost T.A., Lambert M.H., Leesnitzer M.A., McCauley P., McGeehan G., Mitchell J., Moyer M., Pahel G., Rocque W., Overton L.K., Schoenen F., Seaton T., Su J.L., Becherer J.D., et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997, 385:733-736.
15. Arribas J., Esselens C. ADAM17 as a therapeutic target in multiple diseases. Curr. Pharm. Des. 2009, 15:2319-2335.
16. Ortiz C., Caja L., Sancho P., Bertran E., Fabregat I. Inhibition of the EGF receptor blocks autocrine growth and increases the cytotoxic effects of doxorubicin in rat hepatoma cells: role of reactive oxygen species production and glutathione depletion. Biochem. Pharmacol. 2008, 75:1935-1945.
17. Evans J.P. Fertilin beta and other ADAMs as integrin ligands: insights into cell adhesion and fertilization. BioEssays 2001, 23:628-639.
18. White J.M. ADAMs: modulators of cell-cell and cell-matrix interactions. Curr. Opin. Cell Biol. 2003, 15:598-606.
19. Schwettmann L., Wehmeier M., Jokovic D., Aleksandrova K., Brand K., Manns M.P., Lichtinghagen R., Bahr M.J. Hepatic expression of a disintegrin and metalloproteinase (ADAM) and ADAMs with thrombospondin motives (ADAM-TS) enzymes in patients with chronic liver diseases. J. Hepatol. 2008, 49:243-250.
20. Wolfsberg T.G., Primakoff P., Myles D.G., White J.M. ADAM, a novel family of membrane proteins containing A Disintegrin And Metalloprotease domain: multipotential functions in cell-cell and cell-matrix interactions. J. Cell Biol. 1995, 131:275-278.
21. Wolfsberg T.G., Straight P.D., Gerena R.L., Huovila A.P., Primakoff P., Myles D.G., White J.M. ADAM, a widely distributed and developmentally regulated gene family encoding membrane proteins with a disintegrin and metalloprotease domain. Dev. Biol. 1995, 169:378-383.
22. Stone A.L., Kroeger M., Sang Q.X. Structure-function analysis of the ADAM family of disintegrin-like and metalloproteinase-containing proteins. J Protein Chem. 1999, 18:447-465.
23. Black R.A., White J.M. ADAMs: focus on the protease domain. Curr. Opin. Cell Biol. 1998, 10:654-659.
24. Reiss K., Saftig P. The, "a disintegrin and metalloprotease" (ADAM) family of sheddases: physiological and cellular functions. Semin. Cell Dev. Biol. 2009, 20:126-137.
25. Weskamp G., Kratzschmar J., Reid M.S., Blobel C.P. MDC9, a widely expressed cellular disintegrin containing cytoplasmic SH3 ligand domains. J. Cell Biol. 1996, 132:717-726.
26. Hotoda N., Koike H., Sasagawa N., Ishiura S. A secreted form of human ADAM9 has an alpha-secretase activity for APP. Biochem. Biophys. Res. Commun. 2002, 293:800-805.
27. Shi Z., Xu W., Loechel F., Wewer U.M., Murphy L.J. ADAM 12, a disintegrin metalloprotease, interacts with insulin-like growth factor-binding protein-3. J. Biol. Chem. 2000, 275:18574-18580.
28. Laigaard J., Sorensen T., Frohlich C., Pedersen B.N., Christiansen M., Schiott K., Uldbjerg N., Albrechtsen R., Clausen H.V., Ottesen B., Wewer U.M. ADAM12: a novel first-trimester maternal serum marker for Down syndrome. Prenat. Diagn. 2003, 23:1086-1091.
29. O'Shea C., McKie N., Buggy Y., Duggan C., Hill A.D., McDermott E., O'Higgins N., Duffy M.J. Expression of ADAM-9 mRNA and protein in human breast cancer. Int. J. Cancer 2003, 105:754-761.
30. Izumi Y., Hirata M., Hasuwa H., Iwamoto R., Umata T., Miyado K., Tamai Y., Kurisaki T., Sehara-Fujisawa A., Ohno S. A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J. 1998, 17:7260-7272.
31. Schwettmann L., Tschesche H. Cloning and expression in Pichia pastoris of metalloprotease domain of ADAM 9 catalytically active against fibronectin. Protein Expr. Purif. 2001, 21:65-70.
32. Le Pabic H., Bonnier D., Wewer U.M., Coutand A., Musso O., Baffet G., Clement B., Theret N. ADAM12 in human liver cancers: TGF-beta-regulated expression in stellate cells is associated with matrix remodeling. Hepatology 2003, 37:1056-1066.
33. Primakoff P., Hyatt H., Tredick-Kline J. Identification and purification of a sperm surface protein with a potential role in sperm-egg membrane fusion. J. Cell Biol. 1987, 104:141-149.
34. Yagami-Hiromasa T., Sato T., Kurisaki T., Kamijo K., Nabeshima Y., Fujisawa-Sehara A. A metalloprotease-disintegrin participating in myoblast fusion. Nature 1995, 377:652-656.
35. Yong V.W. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat. Rev. Neurosci. 2005, 6:931-944.
36. Yang P., Baker K.A., Hagg T. A disintegrin and metalloprotease 21 (ADAM21) is associated with neurogenesis and axonal growth in developing and adult rodent CNS. J. Comp. Neurol. 2005, 490:163-179.
37. Pupa S.M., Menard S., Forti S., Tagliabue E. New insights into the role of extracellular matrix during tumor onset and progression. J. Cell Physiol. 2002, 192:259-267.
38. Friedl P., Wolf K. Tube travel: the role of proteases in individual and collective cancer cell invasion. Cancer Res. 2008, 68:7247-7249.
39. Wolf K., Friedl P. Mapping proteolytic cancer cell-extracellular matrix interfaces. Clin. Exp. Metastasis 2009, 26:289-298.
40. Chang C., Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol. 2001, 11:S37-43.
41. Wu E., Croucher P.I., McKie N. Expression of members of the novel membrane linked metalloproteinase family ADAM in cells derived from a range of haematological malignancies. Biochem. Biophys. Res. Commun. 1997, 235:437-442.
42. Zhang X.P., Kamata T., Yokoyama K., Puzon-McLaughlin W., Takada Y. Specific interaction of the recombinant disintegrin-like domain of MDC-15 (metargidin, ADAM-15) with integrin alphavbeta 3. J. Biol. Chem. 1998, 7345-7350.
43. Horiuchi K., Weskamp G., Lum L., Hammes H.P., Cai H., Brodie T.A., Ludwig T., Chiusaroli R., Baron R., Preissner K.T., Manova K., Blobel C.P. Potential role for ADAM15 in pathological neovascularization in mice. Mol. Cell. Biol. 2003, 23:5614-5624.
44. Najy A.J., Day K.C., Day M.L. ADAM15 supports prostate cancer metastasis by modulating tumor cell-endothelial cell interaction. Cancer Res. 2008, 68:1092-1099.
45. Kveiborg M., Albrechtsen R., Couchman J.R., Wewer U.M. Cellular roles of ADAM12 in health and disease. Int. J. Biochem. Cell Biol. 2008, 40:1685-1702.
46. Thodeti C.K., Fröhlich C., Nielsen C.K., Holck P., Sundberg C., Kveiborg M., Mahalingam Y., Albrechtsen R., Couchman J.R., Wewer U.M. Hierarchy of ADAM12 binding to integrins in tumor cells. Exp. Cell Res. 2005, 309:438-450.
47. Thodeti C.K., Albrechtsen R., Grauslund M., Asmar M., Larsson C., Takada Y., Mercurio A.M., Couchman J.R., Wewer U.M. ADAM12/syndecan-4 signaling promotes beta 1 integrin-dependent cell spreading through protein kinase Calpha and RhoA. J Biol Chem. 2003, 278:9576-9584.
48. Kveiborg M., Frohlich C., Albrechtsen R., Tischler V., Dietrich N., Holck P., Kronqvist P., Rank F., Mercurio A.M., Wewer U.M. A role for ADAM12 in breast tumor progression and stromal cell apoptosis. Cancer Res. 2005, 65:4754-4761.
49. Fritzsche F.R., Wassermann K., Jung M., Tolle A., Kristiansen I., Lein M., Fritzsche F.R., Wassermann K., Jung M., Tolle A., Kristiansen I., Lein M., Johannsen M., Dietel M., Jung K., Kristiansen G. ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression. BMC Cancer 2008, 8:179.
50. Fritzsche F.R., Jung M., Tolle A., Wild P., Hartmann A., Wassermann K., Rabien A., Lein M., Dietel M., Pilarsky C., Calvano D., Grutzmann R., Jung K., Kristiansen G. ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur.Uro 2008, 54:1097-1106.
51. Sung S.Y., Kubo H., Shigemura K., Arnold R.S., Logani S., Wang R., Konaka H., Nakagawa M., Mousses S., Amin M., Anderson C., Johnstone P., Petros J.A., Marshall F.F., Zhau H.E., Chung L.W. Oxidative stress induces ADAM9 protein expression in human prostate cancer cells. Cancer Res. 2006, 66:9519-9526.
52. Peduto L., Reuter V.E., Shaffer D.R., Scher H.I., Blobel C.P. Critical function for ADAM9 in mouse prostate cancer. Cancer Res. 2005, 65:9312-9319.
53. Yamada D., Ohuchida K., Mizumoto K., Ohhashi S., Yu J., Egami T., Fujita H., Nagai E., Tanaka M. Increased expression of ADAM 9 and ADAM 15 mRNA in pancreatic cancer. Anticancer Res. 2007, 27:793-799.
54. Alldinger I., Dittert D., Peiper M., Fusco A., Chiappetta G., Staub E., Lohr M., Jesnowski R., Baretton G., Ockert D., Saeger H.D., Grutzmann R., Pilarsky C. Gene expression analysis of pancreatic cell lines reveals genes overexpressed in pancreatic cancer. Pancreatology 2005, 5:370-379.
55. Grutzmann R., Luttges J., Sipos B., Ammerpohl O., Dobrowolski F., Alldinger I., Kersting S., Ockert D., Koch R., Kalthoff H., Schackert H.K., Saeger H.D., Kloppel G., Pilarsky C. ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br. J. Cancer 2004, 90:1053-1058.
56. Carl-McGrath S., Lendeckel U., Ebert M., Roessner A., Rocken C. The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int. J. Oncol. 2005, 26:17-24.
57. Shintani Y., Higashiyama S., Ohta M., Hirabayashi H., Yamamoto S., Yoshimasu T., Matsuda H., Matsuura N. Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis. Cancer Res. 2004, 64:4190-4196.
58. Chin K., DeVries S., Fridlyand J., Spellman P.T., Roydasgupta R., Kuo W.L., Lapuk A., Neve R.M., Qian Z., Ryder T., Chen F., Feiler H., Tokuyasu T., Kingsley C., Dairkee S., Meng Z., Chew K., Pinkel D., Jain A., Ljung B.M., Esserman L., Albertson D.G., Waldman F.M., Gray J.W. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cel 2006, 10:I529-541.
59. Franovic A., Robert I., Smith K., Kurban G., Pause A., Gunaratnam L., Lee S. Multiple acquired renal carcinoma tumor capabilities abolished upon silencing of ADAM17. Cancer Res. 2006, 66:8083-8090.
60. Mitsui Y., Mochizuki S., Kodama T., Shimoda M., Ohtsuka T., Shiomi T., Chijiiwa M., Ikeda T., Kitajima M., Okada Y. ADAM28 is overexpressed in human breast carcinomas: implications for carcinoma cell proliferation through cleavage of insulin-like growth factor binding protein-3. Cancer Res. 2006, 66:9913-9920.
61. Ohtsuka T., Shiomi T., Shimoda M., Kodama T., Amour A., Murphy G., Ohuchi E., Kobayashi K., Okada Y. ADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis. Int. J. Cancer 2006, 118:263-273.
62. Tlsty T.D., Coussens L.M. Tumor stroma and regulation of cancer development. Annu Rev Pathol. 2006, 1:119-150.
63. Liotta L.A., Kohn E.C. The microenvironment of the tumour-host interface. Nature 2001, 411:375-379.
64. Lockwood D.S., Yeadon T.M., Clouston A.D., Crawford D.G., Fawcett J., Callaghan S.A., Gotley D.C. Tumor progression in hepatocellular carcinoma: relationship with tumor stroma and parenchymal disease. J. Gastroenterol. Hepatol. 2003, 411:666-672.
65. Desmouliere A., Guyot C., Gabbiani G. The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int. J. Dev. Biol. 2004, 48:509-517.
66. Giannelli G., Quaranta V., Antonaci S. Tissue remodelling in liver diseases. Histol. Histopathol. 2003, 18:1267-1274.
67. Giannelli G., Fransvea E., Bergamini C., Marinosci F., Antonaci S. Laminin-5 chains are expressed differentially in metastatic and nonmetastatic hepatocellular carcinoma. Clin. Cancer Res. 2003, 9:3684-3691.
68. Giannelli G., Bergamini C., Fransvea E., Sgarra C., Antonaci S. Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology 2005, 129:1375-1383.
69. Marongiu F., Doratiotto S., Montisci S., Pani P., Laconi E. Liver repopulation and carcinogenesis: two sides of the same coin?. Am. J. Pathol. 2008, 172:857-864.
70. Giannelli G., Antonaci S. Novel concepts in hepatocellular carcinoma: from molecular research to clinical practice. J. Clin. Gastroenterol. 2006, 40:842-846.
71. Mazzocca A., Fransvea E., Dituri F., Lupo L., Antonaci S., Giannelli G. Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. Hepatology 2009, 9.
72. Mazzocca A., Fransvea E., Lavezzari G., Antonaci S., Giannelli G. Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology 2009, 50:1140-1151.
73. Gregoire M., Lieubeau B. The role of fibroblasts in tumor behavior. Cancer Metastasis Rev. 1995, 14:339-350.
74. Park C.C., Bissell M.J., Barcellos-Hoff M.H. The influence of the microenvironment on the malignant phenotype. Mol. Med. Today 2000, 6:324-329.
75. Ronnov-Jessen L., Petersen O.W., Bissell M.J. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol. Rev. 1996, 76:69-125.
76. Schurch W., Seemayer T.A., Gabbiani G. The myofibroblast: a quarter century after its discovery. Am. J. Surg. Pathol. 1998, 22:141-147.
77. Olumi A.F., Grossfeld G.D., Hayward S.W., Carroll P.R., Tlsty T.D., Cunha G.R. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999, 59:5002-5011.
78. De Wever O., Demetter P., Mareel M., Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int. J. Cancer 2008, 123:2229-3228.
79. Mazzocca A., Carloni V. The metastatic process: methodological advances and pharmacological challenges. Curr. Med. Chem. 2009, 16:1704-1717.
80. Antonaci S., Giannelli G. Rationale for new drugs targeting the tissue microenvironment in patients with HCC. Curr. Pharm. Des. 2007, 13:3288-3291.
81. Tannapfel A., Anhalt K., Hausermann P., Sommerer F., Benicke M., Uhlmann D., Witzigmann H., Hauss J., Wittekind C. Identification of novel proteins associated with hepatocellular carcinomas using protein microarrays. J. Pathol. 2003, 201:238-249.
82. Ding X., Yang L.Y., Huang G.W., Wang W., Lu W.Q. ADAM17 mRNA expression and pathological features of hepatocellular carcinoma. World J. Gastroenterol. 2004, 10:2735-2739.
83. Massagué J. TGFbeta in cancer. Cell 2008, 134:215-230.
84. Murillo M.M., del Castillo G., Sánchez A., Fernández M., Fabregat I. Involvement of EGF receptor and c-Src in the survival signals induced by TGF-beta1 in hepatocytes. Oncogene 2005, 24:4580-4587.
85. Caja L., Ortiz C., Bertran E., Murillo M.M., Miró-Obradors M.J., Palacios E., Fabregat I. Differential intracellular signalling induced by TGF-beta in rat adult hepatocytes and hepatoma cells: implications in liver carcinogenesis. Cell. Signal. 2007, 19:683-694.
86. Mazzocca A., Coppari R., De Franco R., Cho J.Y., Libermann T.A., Pinzani M., Toker A. A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res. 2005, 65:4728-4738.
87. Bourd-Boittin K., Basset L., Bonnier D., L'helgoualc'h A., Samson M., Théret N. CX3CL1/fractalkine shedding by human hepatic stellate cells: contribution to chronic inflammation in the liver. J Cell Mol Med. 2009, 13:1526-1535.
88. Bourd-Boittin K., Le Pabic H., Bonnier D., L'Helgoualc'h A., Théret N. RACK1, a new ADAM12 interacting protein. Contribution to liver fibrogenesis. J Biol Chem. 2008, 283:26000-26009.
89. Itabashi H., Maesawa C., Oikawa H., Kotani K., Sakurai E., Kato K., Komatsu H., Nitta H., Kawamura H., Wakabayashi G., Masuda T. Angiotensin II and epidermal growth factor receptor cross-talk mediated by a disintegrin and metalloprotease accelerates tumor cell proliferation of hepatocellular carcinoma cell lines. Hepatol. Res. 2008, 38:601-613.
90. Castillo J., Erroba E., Perugorría M.J., Santamaría M., Lee D.C., Prieto J., Avila M.A., Berasain C. Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res. 2006, 66:6129-6138.
91. Tsai W.C., Hsu P.W., Lai T.C., Chau G.Y., Lin C.W., Chen C.M., Lin C.D., Liao Y.L., Wang J.L., Chau Y.P., Hsu M.T., Hsiao M., Huang H.D., Tsou A.P. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 2009, 49:1571-1582.